Mult Scler Relat Disord. In multiple sclerosis (MS), the immune damage to the central nervous system results from the net balance between self-reactive and immunoregulatory cells, among other factors. The implication of CD20 + T cells in multiple sclerosis remains to be fully elucidated, and the biological role of the CD20 molecule is unclear. Disease-modifying therapies targeting T cells have, indeed, shown remarkable efficacy in patients with relapsing-remitting MS. Published: November 27, 2019. All antibodies deplete cells expressing CD20, a surface antigen present on maturating B cells, from pre-B cells to plasmablasts, precursors of plasma cells , as well as a population of T cells. Introduction. Here, we studied how anti-CD20 treatment influences B cells in bone marrow, blood, lymph nodes, and spleen in models of experimental … B cells play a vital function in multiple sclerosis (MS) pathogenesis through an array of effector functions. Add comment. Reassessing B cell contributions in multiple sclerosis . Front. Cite. 1. In Archive.
Share This Paper. While it was long held that T cells were the primary mediators of multiple sclerosis (MS) pathogenesis, the beneficial effects observed in response to treatment with Rituximab (RTX), a monoclonal antibody (mAb) targeting CD20, shed light on a key contributor to MS that had been previously underappreciated: B … Save to Library. Launch Research Feed. CD20 + cells comprise both CD8 and CD4 T cell subtypes and are depleted with CD20 + B cells during rituximab therapy (Wilk et al., 2009). The recently successful targeting of B cells in patients with multiple sclerosis (MS) using monoclonal antibodies (mAbs) targeting CD20 has established that it is no longer a question of whether B cells contribute, but how they contribute, to MS disease activity. While antigen-activated B cells differentiate into antibody-secreting plasma cells and serve as potent APCs, naïve B cells are substantially weaker APCs and may exert anti-inflammatory properties modulating effector function of other immune cells. The anti-CD20 antibody ocrelizumab, approved for treatment of multiple sclerosis, leads to rapid elimination of B cells from the blood. The recently successful targeting of B cells in patients with multiple sclerosis (MS) using monoclonal antibodies (mAbs) targeting CD20 has established that it is no longer a question of whether B cells contribute, but how they contribute, to MS disease activity. It is instrumental to recognize that the role of B cells in MS is diverse. Multiple sclerosis (MS) was previously thought to be a T-cell-mediated, demyelinating disease of the central nervous system. However, these therapies do also target B cells, … Treatment of multiple sclerosis with Anti-CD 20 antibodies @inproceedings{Barun2011TreatmentOM, title={Treatment of multiple sclerosis with Anti-CD 20 antibodies}, author={Barbara Barun}, year={2011} } Barbara Barun; Published 2011; Medicine; Please cite this article as: B. Barun, Alternate Sources.